Drugs / FluQuadri
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 42 trials | ||||||
| Phase 4 | NCT03330132 | Oct 2017 → Dec 2025 | influenza | The University of Hong Kong | Completed | No outcome recorded |
| Phase 4 | NCT02957890 | Nov 2016 → Sep 2025 overdue | influenza | The University of Hong Kong | Active not recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT03527355 Background | Apr → Jul 2018 | typhoid fever | International Vaccine Institute | Completed | No outcome recorded |
| Phase 3 | NCT06054269 Comparator | Nov 2022 → Jul 2023 | influenza | Centers for Disease Control and Prevention | Completed | Mixed |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FluQuadri | “Round 1 (November): 0.5mL FluQuadri®, Sanofi Pasteur, containing 60μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the northern...” NCT02957890 ↗3“0.5mL FluQuadri®, Sanofi Pasteur, containing 60μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the northern hemisphere formulation.” NCT03330132 ↗ |
| Modality | Vaccine | “standard inactivated influenza vaccine” NCT03330132 ↗ |
| Route | Intramuscular | “intramuscular dose of FluQuadri” NCT06054269 ↗ |